You are here

  • Home
  • Archive
  • Volume 38, Issue 6
  • The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Aβ load in brain

Article info

Article menu
Download PDFPDF
Original article
The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Aβ load in brain

Authors

  • Jean-Charles Lambert aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • David M A Mann aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Judith M Harris aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Marie-Christine Chartier-Harlin aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Alistair Cumming aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • John Coates aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Helen Lemmon aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • David StClair aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Takeshi Iwatsubo aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  • Corinne Lendon aMolecular Psychiatry Department, Division of Neuroscience, Queen Elizabeth Psychiatry Hospital, University of Birmingham, Birmingham B15 2QZ, UK, bLaboratory Medicine Academic Group, Department of Medicine, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK, cINSERM 508, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cédex, France, dDepartment of Mental Health, Foresterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK, eDepartment of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan PubMed articlesGoogle scholar articles
  1. Dr Lendon, c.l.lendon{at}bham.ac.uk
View Full Text

Citation

Lambert J, Mann DMA, Harris JM, et al
The −48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Aβ load in brain
Journal of Medical Genetics 2001;38:353-355.

Publication history

  • Revised March 29, 2001
  • Accepted April 3, 2001
  • First published June 1, 2001.
Online issue publication 
March 15, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Journal of Medical Genetics